CClinicalTrials.gg
CompletedNCT06167395B-AC3Updated May 17, 2024

Study to Analyze the Aerobic Performance Efficacy of Chronic Intake With a β-alanine Supplement in Recreational Cyclists

An interventional study of Beta Alanine high dose and Beta Alanine low dose in Beta Alanine Supplementation, sponsored by Universidad Católica San Antonio de Murcia. Completed at 1 site in Spain. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Universidad Católica San Antonio de Murcia · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

Randomized, controlled, double-blind, double-blind clinical trial, with three parallel arms depending on the product consumed (experimental product dose 1 and dose 2 and placebo product) and single-center, to measure the efficacy of a sustained release beta alanine on the aerobic performance efficacy in recreational cyclist

Read the detailed description

Subjects meeting the selection criteria will be randomly assigned to each of the study groups (investigational product dose 1 or dose 2, or placebo, depending on the group to which they have been assigned).

The product to be consumed is beta alanine. Participants will consume the product for 30 days. They will have to take 4 intakes every three hours, being the first intake two hours after waking up.

The study subjects will have to make 2 visits to the laboratory. At the first and last visit, their aerobic performance will be evaluated by an incremental test to exhaustion with gas analysis.

02

Conditions studied

  • Beta Alanine Supplementation

Keywords

  • Aerobic Performance
  • Beta Alanine
  • Supplementation
03

In context

Lead sponsor

Universidad Católica San Antonio de Murcia is the lead sponsor of 132 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male cyclists with more than two years of cycling experience.
  • Perform tests without fatigue.
  • Road bike training at least twice a week.

Exclusion criteria

Exclusion Criteria:

  • Participants with chronic illness.
  • Have a long-term injury that prevents you from training in the previous month.
  • Inability to understand informed consent.
  • Have consumed beta alanine in the three years prior to the start of the study.
  • Consumption of other supplements that may alter performance.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Beta Alanine high dose

    Consumption for 30 days.

    Dietary Supplement: Beta Alanine high dose

  • Experimental
    Beta Alanine low dose

    Consumption for 30 days.

    Dietary Supplement: Beta Alanine low dose

  • Placebo comparator
    Control group

    Consumption for 30 days.

    Dietary Supplement: Control product

Interventions

  • Dietary supplementBeta Alanine high dose

    Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.

  • Dietary supplementBeta Alanine low dose

    Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.

  • Dietary supplementControl product

    Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.

06

What researchers measure

Primary outcomes

  1. Power

    Measured using a cyclus 2 roller.

    Time frame: Change in performance after 30 days of product consumption

  2. Distance

    Measured using a cyclus 2 roller.

    Time frame: Change in performance after 30 days of product consumption

Secondary outcomes

  1. Anaerobic treshold

    Through a stress test with gas analysis

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

  2. Maximum oxygen consumption

    Through a stress test with gas analysis

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

  3. Aerobic threshold

    Through a stress test with gas analysis

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

  4. Microcapillary blood

    This test provides biochemical variables (ABL90FLEX) with 70 ml of capillary blood.

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

  5. Lactate

    Lactate levels will be measured using the Lactate Pro 2

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

  6. Heart Rate

    The heart rate will be evaluated by means of a heart rate strap.

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

  7. Fatigue

    Rate of perceived exertion

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

07

Study locations

1 site
  • Catholic University of Murcia
    Murcia, 30107, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06167395
Lead sponsor
Universidad Católica San Antonio de Murcia
Responsible party
Francisco Javier López Román (Principal Investigator, Universidad Católica San Antonio de Murcia) — Principal investigator
First posted
Dec 12, 2023
Start date
Dec 4, 2023
Primary completion
Feb 19, 2024
Completion
Mar 29, 2024
Last update
May 17, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion